Preferred Label : dolutegravir;

MeSH note : an HIV-1 integrase inhibitor; InChIKey RHWKPHLQXYSBKR-BMIGLBTASA-N;

CISMeF synonym : S-GSK1349572; S/GSK1349572; (4R,9aS)-5-hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide;

MeSH synonym : (4R,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide;

MeSH hyponym : GSK-1349572; GSK1349572A; GSK-1349572A; (4S,12aS)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide; Tivicay PD; (4S,12aR)-N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide;

MeSH CAS label : 2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9- carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a- hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-;

MeSH Related Number : 0E1T06685X; 1Q1V9V5WYQ; FGD6SPP2VH; S3BN9Q9EHW;

Is substance : O;

UNII : DKO1W9H7M1;

InChIKey : RHWKPHLQXYSBKR-BMIGLBTASA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3497014/fr/dovato-dolutegravir/lamivudine-antiretroviraux
2024
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
lamivudine
dolutegravir sodium
dolutegravir
Dolutegravir Sodium/Lamivudine
hiv infections
HIV-1
adult
adolescent
lamivudine and dolutegravir
administration, oral
evaluation of the transparency committee
anti-retroviral agents

---
https://www.has-sante.fr/jcms/p_3293338/fr/juluca-50-mg/25-mg-rilpivirine-/-dolutegravir
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
dolutegravir, rilpivirine drug combination
dolutegravir
anti-hiv agents
dolutegravir and rilpivirine
hiv infections
HIV-1
adult
antiviral agents
pregnancy
HIV integrase inhibitors
reverse transcriptase inhibitors
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3280958/fr/tivicay-dolutegravir-sodique-vih-pediatrique
2021
false
false
false
France
evaluation of the transparency committee
dolutegravir sodium
tivicay
dolutegravir

---
https://www.has-sante.fr/jcms/p_3293335/fr/tivicay-dolutegravir-sodique
2021
false
false
false
France
hiv infections
adult
adolescent
child
treatment outcome
insurance, health, reimbursement
dolutegravir
teratogens
pregnancy
evaluation of the transparency committee
dolutegravir sodium
HIV integrase inhibitors
dolutegravir
heterocyclic compounds, 3-ring
oxazines
piperazines
pyridones

---
https://www.has-sante.fr/jcms/p_3146844/fr/dovato
2020
false
false
false
France
lamivudine and dolutegravir
drug combinations
dolutegravir
administration, oral
treatment outcome
lamivudine
hiv infections
HIV-1
adult
adolescent
reverse transcriptase inhibitors
anti-hiv agents
HIV integrase inhibitors
evaluation of the transparency committee
heterocyclic compounds, 3-ring

---
https://www.ema.europa.eu/en/medicines/human/EPAR/dovato
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
dolutegravir
dolutegravir
drug approval
europe
HIV integrase inhibitors
HIV integrase inhibitors
lamivudine
lamivudine
drug combinations
adult
adolescent
hiv infections
administration, oral
reverse transcriptase inhibitors
reverse transcriptase inhibitors
anti-hiv agents
anti-hiv agents
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
lamivudine and dolutegravir
drug evaluation, preclinical
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/dovato-infection-vih-4797.html
2019
false
false
false
Canada
French
drug evaluation
drug combinations
dolutegravir
HIV integrase inhibitors
lamivudine
administration, oral
reverse transcriptase inhibitors
hiv infections
HIV-1
Cost-Benefit analysis
lamivudine and dolutegravir
heterocyclic compounds, 3-ring

---
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca-dolutegravir/rilpivirine-association-d-antiviraux
2018
false
false
false
France
French
drug combinations
dolutegravir and rilpivirine
treatment outcome
HIV integrase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
evaluation of the transparency committee
guidelines for drug use
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination

---
https://www.ema.europa.eu/medicines/human/EPAR/Juluca
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Rilpivirine
dolutegravir
drug combinations
dolutegravir and rilpivirine
drug approval
europe
treatment outcome
HIV integrase inhibitors
HIV integrase inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
dolutegravir, rilpivirine drug combination

---
New safety information for women using dolutegravir, a medication used to treat HIV infection
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67010a-fra.php
2018
false
false
false
Canada
French
English
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
patient education handout
heterocyclic compounds, 3-ring

---
https://www.ansm.sante.fr/actualites/anomalies-de-fermeture-du-tube-neural-chez-les-enfants-nes-de-meres-traitees-par-le-dolutegravir-pendant-la-grossesse
2018
false
false
false
France
French
pharmacovigilance note
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
guidelines for drug use
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
Obstetrician (occupation)
Gynecologist (occupation)
Sexual Health
heterocyclic compounds, 3-ring

---
TIVICAY, TRIUMEQ and JULUCA (dolutegravir containing medicines) – Possible Risk of Neural Tube Defects
Destinataires : Professionnels de la santé, y compris spécialistes des maladies infectieuses, spécialistes du virus de l’immunodéficience humaine (VIH) et infirmiers(ères), virologues cliniques, obstétriciens(ennes), gynécologues, pédiatres, spécialistes de la santé sexuelle, pharmaciens(ennes) et omnipraticiens(ennes).
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66998a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
guidelines for drug use
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
Abacavir/Dolutegravir/Lamivudine
Rilpivirine

---
https://www.has-sante.fr/portail/jcms/c_2801228/fr/tivicay-dolutegravir-inhibiteur-de-l-integrase
https://www.has-sante.fr/portail/jcms/c_2801228/fr/tivicay
2017
false
false
false
France
French
evaluation of the transparency committee
dolutegravir sodium
dolutegravir sodium
dolutegravir
dolutegravir
dolutegravir
administration, oral
hiv infections
HIV-1
adolescent
drug therapy, combination
HIV integrase inhibitors
HIV integrase inhibitors
treatment outcome
insurance, health, reimbursement
drug resistance, viral
guidelines for drug use
child
continuity of patient care
human immunodeficiency virus i infection
Genotype drug resistance test
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64287253
2015
false
false
false
France
French
summary of product characteristics
evaluation of the transparency committee
package leaflet
lamivudine, abacavir and dolutegravir
lamivudine
abacavir sulfate
dolutegravir sodium
drug combinations
abacavir
dolutegravir
dideoxynucleosides
heterocyclic compounds, 3-ring

---
Summary Basis of Decision (SBD) for Tivicay
Dolutegravir (as dolutegravir sodium), 50 mg, Tablets
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00196
2014
false
Canada
French
English
drug information
dolutegravir
dolutegravir
canada
drug approval
administration, oral
hiv infections
dolutegravir
HIV integrase inhibitors
adult
drug therapy, combination
treatment outcome
HIV integrase inhibitors
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
Product containing dolutegravir in oral dose form (medicinal product form)

---
http://www.has-sante.fr/portail/jcms/c_2008464/fr/triumeq
http://www.has-sante.fr/portail/jcms/c_2008464/fr/triumeq-dolutegravir/abacavir/lamivudine-association-fixe-d-antiretroviraux
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
administration, oral
insurance, health, reimbursement
treatment outcome
drug combinations
dolutegravir
dolutegravir
abacavir
abacavir
lamivudine
lamivudine
lamivudine, abacavir and dolutegravir
reverse transcriptase inhibitors
reverse transcriptase inhibitors
anti-hiv agents
anti-hiv agents
HIV integrase inhibitors
HIV integrase inhibitors
adult
adolescent
hiv infections
HIV-1
HLA-B*57:01 antigen
human immunodeficiency virus i infection
Contraindications, Procedure
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
dideoxynucleosides
dideoxynucleosides
HLA-B antigens
Contraindications, Drug

---
https://www.ema.europa.eu/medicines/human/EPAR/Tivicay
2014
false
United Kingdom
English
French
dolutegravir
dolutegravir
drug approval
europe
dolutegravir
HIV integrase inhibitors
HIV integrase inhibitors
adult
drug therapy, combination
administration, oral
hiv infections
adolescent
treatment outcome
summary of product characteristics
package leaflet
drug evaluation
syndication feed
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring

---
http://www.has-sante.fr/portail/jcms/c_1748396/fr/tivicay
http://www.has-sante.fr/portail/jcms/c_1748396/fr/tivicay-50-mg-dolutegravir-inhibiteur-de-lintegrase
2014
false
false
false
France
French
evaluation of the transparency committee
dolutegravir sodium
dolutegravir sodium
dolutegravir
dolutegravir
dolutegravir
administration, oral
hiv infections
HIV-1
adult
adolescent
drug therapy, combination
HIV integrase inhibitors
HIV integrase inhibitors
treatment outcome
insurance, health, reimbursement
clinical trials as topic
drug resistance, viral
guidelines for drug use
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62685155
2014
false
false
false
France
French
summary of product characteristics
package leaflet
dolutegravir
compression, nos
tablets
dolutegravir
dandruff
pill, nos
seborrhea sicca
dandruff
heterocyclic compounds, 3-ring

---
Nous contacter.
26/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.